Vioxx VIGOR Label Talks Proceeding; Merck “Confident” Of Positive Outcome
Executive Summary
Merck is confident it will incorporate the VIGOR gastrointestinal safety results into the Vioxx label following completion of negotiations with FDA
You may also be interested in...
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events
Merck revises Arcoxia NDA
Merck is withdrawing the NDA for its COX-2 inhibitor Arcoxia (etoricoxib) and refiling with additional ankylosing spondylitis efficacy data. "Merck believes the new data, along with the data previously submitted, will provide a fuller picture of the product's safety and efficacy and will position it more favorably for approval in the U.S." Additional studies are not needed; Merck has the ankylosing spondylitis data on hand. Merck filed the Vioxx follow-on Oct. 11. Arcoxia may be reviewed by FDA's Arthritis Advisory Committee in mid-May (1"The Pink Sheet" March 4, In Brief)...